CG Oncology, Inc. (CGON)
| Market Cap | 2.40B |
| Revenue (ttm) | 684,000 |
| Net Income (ttm) | -78.73M |
| Shares Out | 67.63M |
| EPS (ttm) | -1.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 79,979 |
| Open | 36.04 |
| Previous Close | 35.77 |
| Day's Range | 35.03 - 36.33 |
| 52-Week Range | 25.77 - 50.23 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 63.88 (+79.82%) |
| Earnings Date | Nov 12, 2024 |
About CGON
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in mus... [Read more]
Financial Performance
In 2023, CG Oncology's revenue was $204,000, an increase of 6.81% compared to the previous year's $191,000. Losses were -$67.80 million, 54.8% more than in 2022.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for CGON stock is "Strong Buy." The 12-month stock price forecast is $63.88, which is an increase of 79.82% from the latest price.
News
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
CG Oncology: Promising Data, But Looks Expensive
CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. Cretostimogene, an oncolytic immunotherapy, works by sele...
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Natur...
CG Oncology Bringing Undervalued Innovation To Bladder Cancer
CG Oncology's cretostimogene shows high potential to disrupt the NMIBC market with promising efficacy and safety data. The company is initially targeting high-risk NMIBC patients who no longer respond...
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
IRVINE, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladde...
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) First Pati...
CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
CG Oncology, Inc. achieved positive results from its phase 3 BOND-003 study using cretostimogene for the treatment of high-risk BCG unresponsive NMIBC patients; Final data expected end of 2024.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today ...
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
IRVINE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone blad...
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
IRVINE, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone blad...
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session - - New 12-month data ...
Protara: A Bombed Out Biotech With A Very Positive Skew
Protara Therapeutics is developing therapies for cancer and rare diseases, with a focus on non-muscle invasive bladder cancer and lymphangiomas.
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares.
American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues
American Healthcare REIT Inc., Fortegra Group Inc. and Fractyle Health Inc. set proposed price ranges in their upcoming initial public offerings on Monday, after a mixed reception to two deals late la...
U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week
Seven IPOs priced this past week, led by 3 that raised $100+ million. Four very small Chinese issuers also began trading in the US this past week, all raising $10 million or less.
Biotech's First IPO of 2024 Popped 96%. What It Means.
Biotech stocks have fallen about 1% so far this year.
CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality
With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year's most highly anticipated IPOs. The company's lead drug targets a sizable addressa...
CG Oncology valued at $1.75 bln in strong market debut
CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq.
CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading
Cancer drug company CG Oncology Inc. priced its initial public offering above its estimated range and added three million shares to the deal in a bullish sign ahead of its trading debut Thursday on th...
CG Oncology Announces Pricing of Upsized Initial Public Offering
IRVINE, Calif.--(BUSINESS WIRE)--CG Oncology Announces Pricing of Upsized Initial Public Offering.
Bladder cancer biotech CG Oncology files for a $100 million IPO
CG Oncology, a Phase 3 biotech developing an oncolytic immunotherapy for bladder cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
CG Oncology Files for IPO, Aims to Boost Bladder Cancer Treatments
CG Oncology, a biopharmaceutical company focused on bladder cancer treatments, has filed for an IPO with the SEC. The firm aims to list on the Nasdaq under the symbol CGON.
CG Oncology IPO Registration Document (S-1)
CG Oncology has filed to go public with an IPO on the NASDAQ.
CG Oncologys bladder cancer drug gets fast track to approval
CG Oncology has received fast track designation and breakthrough designation needed to accelerate US FDA submission.